Form 4: Twist Bioscience CFO Sells Shares for Tax Withholding

Twist Bioscience Corporation's Chief Financial Officer, Adam Laponis, reported a sale of 2,597 shares of common stock on April 9, 2026, to cover tax withholding obligations.

Summary

• Adam Laponis, Chief Financial Officer of Twist Bioscience Corporation, sold 2,597 shares of common stock on April 9, 2026.
• The sale was executed at a price of $49.889 per share.
• These shares were sold to cover tax withholding obligations related to the vesting of Restricted Stock Units.
• This transaction was a mandatory 'sell to cover' as per the company's equity incentive plans and not a discretionary trade.
• Following this transaction, Laponis beneficially owns 125,694 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as the transaction is a standard 'sell to cover' for tax purposes and not indicative of a change in the executive's investment sentiment towards the company.

Negatives

• The CFO sold a portion of his shares, which could be perceived negatively by the market, although it was for tax withholding purposes.

Future Outlook

No forward-looking statements or guidance were provided in this filing.

Industry Context

StockSavvy.ai notes that Form 4 filings are routine disclosures for insider transactions. The 'sell to cover' mechanism for tax withholding is a common practice for executives to manage tax liabilities associated with equity compensation, and typically does not signal a negative view of the company's prospects by the executive.

Stakeholder Impact

• Shareholders: The sale is for tax withholding, not a discretionary sale, so it is unlikely to have a significant negative impact on share price. The remaining beneficial ownership by the CFO remains substantial.

Key Dates

Keywords

Form 4, SEC Filing, Insider Trading, Stock Sale, Tax Withholding, Restricted Stock Units, Twist Bioscience, Adam Laponis, CFO